AC Immune to Showcase Parkinson’s Prevention Strategy and TDP-43 Tracer at AD/PD 2026
Event summary
- AC Immune will host an industry symposium on Parkinson’s disease prevention on March 18, 2026, featuring presentations from academic and industry experts.
- The company will present its first-in-class TDP-43 PET-tracer ACI-19626 at the AD/PD 2026 conference on March 19, 2026.
- Symposium topics include lessons from Alzheimer’s disease, α-synuclein targeting, and interim results from the Phase 2 VacSYn trial of ACI-7104.056.
- AC Immune’s symposium will feature presentations on fluid biomarkers, active immunotherapy, and small molecule targeting of α-synuclein.
The big picture
AC Immune’s focus on Parkinson’s disease prevention aligns with broader industry trends toward early intervention in neurodegenerative diseases. The company’s strategic partnerships and proprietary technology platforms position it to capitalize on the growing demand for precision therapeutics. The potential milestone payments and royalties from these partnerships could significantly enhance its financial standing.
What we're watching
- Clinical Validation
- How the interim results of the Phase 2 VacSYn trial will impact the development of ACI-7104.056.
- Market Differentiation
- Whether AC Immune’s precision prevention approach can position it as a leader in Parkinson’s disease treatment.
- Strategic Partnerships
- The pace at which AC Immune can secure additional partnerships to advance its proprietary programs.
Related topics